SK352000A3 - Piperazine derivatives, process for its preparation and pharmaceutical composition containing same - Google Patents
Piperazine derivatives, process for its preparation and pharmaceutical composition containing same Download PDFInfo
- Publication number
- SK352000A3 SK352000A3 SK35-2000A SK352000A SK352000A3 SK 352000 A3 SK352000 A3 SK 352000A3 SK 352000 A SK352000 A SK 352000A SK 352000 A3 SK352000 A3 SK 352000A3
- Authority
- SK
- Slovakia
- Prior art keywords
- benzopyran
- oxo
- formula
- group
- butyl
- Prior art date
Links
- 150000004885 piperazines Chemical class 0.000 title claims abstract description 13
- 238000000034 method Methods 0.000 title claims description 11
- 238000002360 preparation method Methods 0.000 title claims description 10
- 239000008194 pharmaceutical composition Substances 0.000 title claims description 7
- 230000008569 process Effects 0.000 title claims description 5
- 229940066771 systemic antihistamines piperazine derivative Drugs 0.000 title abstract description 6
- -1 2 -oxo-2H-1-benzopyran-6-yl Chemical group 0.000 claims description 107
- 150000001875 compounds Chemical class 0.000 claims description 65
- 238000011282 treatment Methods 0.000 claims description 24
- 150000003839 salts Chemical class 0.000 claims description 21
- 239000002253 acid Substances 0.000 claims description 19
- 239000004480 active ingredient Substances 0.000 claims description 10
- 239000003814 drug Substances 0.000 claims description 9
- 229910052801 chlorine Inorganic materials 0.000 claims description 8
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 8
- 229910052794 bromium Inorganic materials 0.000 claims description 7
- 125000004432 carbon atom Chemical group C* 0.000 claims description 7
- 239000000460 chlorine Substances 0.000 claims description 7
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 7
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 claims description 6
- 125000000217 alkyl group Chemical group 0.000 claims description 6
- 239000011737 fluorine Substances 0.000 claims description 6
- 229910052731 fluorine Inorganic materials 0.000 claims description 6
- 125000000896 monocarboxylic acid group Chemical group 0.000 claims description 6
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 claims description 5
- 125000006297 carbonyl amino group Chemical group [H]N([*:2])C([*:1])=O 0.000 claims description 5
- 239000003638 chemical reducing agent Substances 0.000 claims description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 5
- 201000010099 disease Diseases 0.000 claims description 4
- 239000007788 liquid Substances 0.000 claims description 4
- 238000004519 manufacturing process Methods 0.000 claims description 4
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 claims description 3
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims description 3
- 239000003795 chemical substances by application Substances 0.000 claims description 3
- 125000001309 chloro group Chemical group Cl* 0.000 claims description 3
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 3
- 229910052757 nitrogen Inorganic materials 0.000 claims description 3
- AQVSBDQLHRNRDQ-UHFFFAOYSA-N 3-[4-[4-(2-oxochromen-4-yl)piperazin-1-yl]butyl]-1h-indole-5-carbonitrile Chemical compound C12=CC=CC=C2OC(=O)C=C1N1CCN(CCCCC=2C3=CC(=CC=C3NC=2)C#N)CC1 AQVSBDQLHRNRDQ-UHFFFAOYSA-N 0.000 claims description 2
- JYRQRDDPHJEJCJ-UHFFFAOYSA-N 3-[4-[4-(2-oxochromen-6-yl)piperazin-1-yl]butyl]-1h-indole-5-carbonitrile Chemical compound C1=C(C#N)C=C2C(CCCCN3CCN(CC3)C=3C=C4C=CC(OC4=CC=3)=O)=CNC2=C1 JYRQRDDPHJEJCJ-UHFFFAOYSA-N 0.000 claims description 2
- CMCPGNNULUGJBT-UHFFFAOYSA-N 6-[4-[4-(5-fluoro-1h-indol-3-yl)butyl]piperazin-1-yl]chromen-2-one Chemical compound O1C(=O)C=CC2=CC(N3CCN(CC3)CCCCC3=CNC4=CC=C(C=C43)F)=CC=C21 CMCPGNNULUGJBT-UHFFFAOYSA-N 0.000 claims description 2
- 241000972349 Ocoa Species 0.000 claims description 2
- 240000001090 Papaver somniferum Species 0.000 claims description 2
- 235000008753 Papaver somniferum Nutrition 0.000 claims description 2
- 239000002552 dosage form Substances 0.000 claims description 2
- 125000000814 indol-3-yl group Chemical group [H]C1=C([H])C([H])=C2N([H])C([H])=C([*])C2=C1[H] 0.000 claims description 2
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 claims description 2
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 2
- 239000007787 solid Substances 0.000 claims description 2
- 125000003944 tolyl group Chemical group 0.000 claims description 2
- AVNYLTOCOWGNHF-UHFFFAOYSA-N 3-[4-[4-(7-hydroxy-2-oxochromen-6-yl)piperazin-1-yl]butyl]-1h-indole-5-carbonitrile Chemical compound C1=C(C#N)C=C2C(CCCCN3CCN(CC3)C3=CC=4C=CC(=O)OC=4C=C3O)=CNC2=C1 AVNYLTOCOWGNHF-UHFFFAOYSA-N 0.000 claims 1
- 206010008118 cerebral infarction Diseases 0.000 abstract description 7
- 230000000694 effects Effects 0.000 abstract description 6
- 206010008120 Cerebral ischaemia Diseases 0.000 abstract description 4
- 208000006011 Stroke Diseases 0.000 abstract description 4
- 230000002401 inhibitory effect Effects 0.000 abstract description 3
- 206010027175 memory impairment Diseases 0.000 abstract description 3
- 201000000980 schizophrenia Diseases 0.000 abstract description 3
- 208000019901 Anxiety disease Diseases 0.000 abstract description 2
- 239000000556 agonist Substances 0.000 abstract description 2
- 230000003389 potentiating effect Effects 0.000 abstract description 2
- 102100022738 5-hydroxytryptamine receptor 1A Human genes 0.000 abstract 1
- 101710138638 5-hydroxytryptamine receptor 1A Proteins 0.000 abstract 1
- 206010029897 Obsessive thoughts Diseases 0.000 abstract 1
- 230000006399 behavior Effects 0.000 abstract 1
- 230000006735 deficit Effects 0.000 abstract 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 31
- 238000006243 chemical reaction Methods 0.000 description 17
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 15
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 15
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 13
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 12
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 10
- 239000000203 mixture Substances 0.000 description 10
- 230000009467 reduction Effects 0.000 description 10
- 238000006722 reduction reaction Methods 0.000 description 10
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 9
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 9
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 9
- 150000007513 acids Chemical class 0.000 description 8
- 239000002585 base Substances 0.000 description 7
- 239000000243 solution Substances 0.000 description 7
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 6
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 6
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 6
- 239000002904 solvent Substances 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 5
- 239000001257 hydrogen Substances 0.000 description 5
- 229910052739 hydrogen Inorganic materials 0.000 description 5
- 150000004702 methyl esters Chemical class 0.000 description 5
- 239000003826 tablet Substances 0.000 description 5
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 5
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 4
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 4
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 4
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 4
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 4
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 4
- 206010043118 Tardive Dyskinesia Diseases 0.000 description 4
- 150000001298 alcohols Chemical class 0.000 description 4
- 150000001408 amides Chemical class 0.000 description 4
- 239000000935 antidepressant agent Substances 0.000 description 4
- 229940005513 antidepressants Drugs 0.000 description 4
- 239000002249 anxiolytic agent Substances 0.000 description 4
- 230000000949 anxiolytic effect Effects 0.000 description 4
- 229940005530 anxiolytics Drugs 0.000 description 4
- 210000003169 central nervous system Anatomy 0.000 description 4
- ZYGHJZDHTFUPRJ-UHFFFAOYSA-N coumarin Chemical compound C1=CC=C2OC(=O)C=CC2=C1 ZYGHJZDHTFUPRJ-UHFFFAOYSA-N 0.000 description 4
- 229910052740 iodine Inorganic materials 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- 150000002825 nitriles Chemical class 0.000 description 4
- 125000006239 protecting group Chemical group 0.000 description 4
- 229940076279 serotonin Drugs 0.000 description 4
- 239000007858 starting material Substances 0.000 description 4
- 125000001424 substituent group Chemical group 0.000 description 4
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 4
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 3
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical group [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 3
- ASXGJMSKWNBENU-UHFFFAOYSA-N 8-OH-DPAT Chemical compound C1=CC(O)=C2CC(N(CCC)CCC)CCC2=C1 ASXGJMSKWNBENU-UHFFFAOYSA-N 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- 201000006474 Brain Ischemia Diseases 0.000 description 3
- 208000032841 Bulimia Diseases 0.000 description 3
- 206010006550 Bulimia nervosa Diseases 0.000 description 3
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 3
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 3
- 208000020358 Learning disease Diseases 0.000 description 3
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 3
- 238000009825 accumulation Methods 0.000 description 3
- 150000001340 alkali metals Chemical class 0.000 description 3
- 150000001412 amines Chemical class 0.000 description 3
- 125000003277 amino group Chemical group 0.000 description 3
- 239000007864 aqueous solution Substances 0.000 description 3
- 230000037396 body weight Effects 0.000 description 3
- 210000004556 brain Anatomy 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- 208000026106 cerebrovascular disease Diseases 0.000 description 3
- 231100000867 compulsive behavior Toxicity 0.000 description 3
- 239000012154 double-distilled water Substances 0.000 description 3
- 201000003723 learning disability Diseases 0.000 description 3
- 229940098779 methanesulfonic acid Drugs 0.000 description 3
- NLKNQRATVPKPDG-UHFFFAOYSA-M potassium iodide Chemical compound [K+].[I-] NLKNQRATVPKPDG-UHFFFAOYSA-M 0.000 description 3
- 238000011321 prophylaxis Methods 0.000 description 3
- 230000009103 reabsorption Effects 0.000 description 3
- 239000011541 reaction mixture Substances 0.000 description 3
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 3
- 239000011734 sodium Substances 0.000 description 3
- 239000012279 sodium borohydride Substances 0.000 description 3
- 229910000033 sodium borohydride Inorganic materials 0.000 description 3
- 239000000829 suppository Substances 0.000 description 3
- 239000000454 talc Substances 0.000 description 3
- 235000012222 talc Nutrition 0.000 description 3
- 229910052623 talc Inorganic materials 0.000 description 3
- 238000010626 work up procedure Methods 0.000 description 3
- ZWEHNKRNPOVVGH-UHFFFAOYSA-N 2-Butanone Chemical compound CCC(C)=O ZWEHNKRNPOVVGH-UHFFFAOYSA-N 0.000 description 2
- HXHURWICSORQBU-UHFFFAOYSA-N 3-[4-[4-(7-methoxy-2-oxochromen-6-yl)piperazin-1-yl]butyl]-1h-indole-5-carboxylic acid Chemical compound C1=C(C(O)=O)C=C2C(CCCCN3CCN(CC3)C3=CC=4C=CC(=O)OC=4C=C3OC)=CNC2=C1 HXHURWICSORQBU-UHFFFAOYSA-N 0.000 description 2
- XTHFKEDIFFGKHM-UHFFFAOYSA-N Dimethoxyethane Chemical compound COCCOC XTHFKEDIFFGKHM-UHFFFAOYSA-N 0.000 description 2
- 208000030814 Eating disease Diseases 0.000 description 2
- 208000019454 Feeding and Eating disease Diseases 0.000 description 2
- 208000012895 Gastric disease Diseases 0.000 description 2
- SIKJAQJRHWYJAI-UHFFFAOYSA-N Indole Chemical compound C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- 238000006147 Japp-Klingemann synthesis reaction Methods 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- 208000019695 Migraine disease Diseases 0.000 description 2
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 2
- SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical compound CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 description 2
- 206010028813 Nausea Diseases 0.000 description 2
- 208000018737 Parkinson disease Diseases 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 208000028017 Psychotic disease Diseases 0.000 description 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
- SMWDFEZZVXVKRB-UHFFFAOYSA-N Quinoline Chemical compound N1=CC=CC2=CC=CC=C21 SMWDFEZZVXVKRB-UHFFFAOYSA-N 0.000 description 2
- NPXOKRUENSOPAO-UHFFFAOYSA-N Raney nickel Chemical class [Al].[Ni] NPXOKRUENSOPAO-UHFFFAOYSA-N 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 239000013543 active substance Substances 0.000 description 2
- 230000010933 acylation Effects 0.000 description 2
- 238000005917 acylation reaction Methods 0.000 description 2
- 229910052783 alkali metal Inorganic materials 0.000 description 2
- 229910001860 alkaline earth metal hydroxide Inorganic materials 0.000 description 2
- 230000029936 alkylation Effects 0.000 description 2
- 238000005804 alkylation reaction Methods 0.000 description 2
- VSCWAEJMTAWNJL-UHFFFAOYSA-K aluminium trichloride Chemical compound Cl[Al](Cl)Cl VSCWAEJMTAWNJL-UHFFFAOYSA-K 0.000 description 2
- 239000000164 antipsychotic agent Substances 0.000 description 2
- 229940005529 antipsychotics Drugs 0.000 description 2
- 125000005279 aryl sulfonyloxy group Chemical group 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- TXFLGZOGNOOEFZ-UHFFFAOYSA-N bis(2-chloroethyl)amine Chemical compound ClCCNCCCl TXFLGZOGNOOEFZ-UHFFFAOYSA-N 0.000 description 2
- WTEOIRVLGSZEPR-UHFFFAOYSA-N boron trifluoride Chemical compound FB(F)F WTEOIRVLGSZEPR-UHFFFAOYSA-N 0.000 description 2
- 229910052799 carbon Inorganic materials 0.000 description 2
- 150000001735 carboxylic acids Chemical class 0.000 description 2
- 239000003054 catalyst Substances 0.000 description 2
- 238000003776 cleavage reaction Methods 0.000 description 2
- 239000003086 colorant Substances 0.000 description 2
- 235000014632 disordered eating Nutrition 0.000 description 2
- 239000008298 dragée Substances 0.000 description 2
- 150000002148 esters Chemical class 0.000 description 2
- 150000002170 ethers Chemical class 0.000 description 2
- 238000004992 fast atom bombardment mass spectroscopy Methods 0.000 description 2
- 230000002496 gastric effect Effects 0.000 description 2
- 150000004820 halides Chemical class 0.000 description 2
- 229930195733 hydrocarbon Natural products 0.000 description 2
- 150000002430 hydrocarbons Chemical class 0.000 description 2
- 238000011065 in-situ storage Methods 0.000 description 2
- 125000001041 indolyl group Chemical group 0.000 description 2
- 239000012442 inert solvent Substances 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 208000028774 intestinal disease Diseases 0.000 description 2
- 239000011630 iodine Substances 0.000 description 2
- SUMDYPCJJOFFON-UHFFFAOYSA-N isethionic acid Chemical compound OCCS(O)(=O)=O SUMDYPCJJOFFON-UHFFFAOYSA-N 0.000 description 2
- PHTQWCKDNZKARW-UHFFFAOYSA-N isoamylol Chemical compound CC(C)CCO PHTQWCKDNZKARW-UHFFFAOYSA-N 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 239000012280 lithium aluminium hydride Substances 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- 229910052987 metal hydride Inorganic materials 0.000 description 2
- 150000004681 metal hydrides Chemical class 0.000 description 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 2
- 230000008693 nausea Effects 0.000 description 2
- 239000002674 ointment Substances 0.000 description 2
- 150000007530 organic bases Chemical class 0.000 description 2
- 229910052763 palladium Inorganic materials 0.000 description 2
- 235000019271 petrolatum Nutrition 0.000 description 2
- 239000012071 phase Substances 0.000 description 2
- 235000011007 phosphoric acid Nutrition 0.000 description 2
- XHXFXVLFKHQFAL-UHFFFAOYSA-N phosphoryl trichloride Chemical compound ClP(Cl)(Cl)=O XHXFXVLFKHQFAL-UHFFFAOYSA-N 0.000 description 2
- 229920001592 potato starch Polymers 0.000 description 2
- 150000003141 primary amines Chemical class 0.000 description 2
- 230000001603 reducing effect Effects 0.000 description 2
- 238000006268 reductive amination reaction Methods 0.000 description 2
- 230000007017 scission Effects 0.000 description 2
- 150000003335 secondary amines Chemical class 0.000 description 2
- 239000003727 serotonin 1A antagonist Substances 0.000 description 2
- 208000019116 sleep disease Diseases 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- HEMHJVSKTPXQMS-UHFFFAOYSA-M sodium hydroxide Inorganic materials [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 2
- 210000000278 spinal cord Anatomy 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 2
- 229910052723 transition metal Inorganic materials 0.000 description 2
- 150000003624 transition metals Chemical class 0.000 description 2
- ASOKPJOREAFHNY-UHFFFAOYSA-N 1-Hydroxybenzotriazole Chemical compound C1=CC=C2N(O)N=NC2=C1 ASOKPJOREAFHNY-UHFFFAOYSA-N 0.000 description 1
- OOSZCNKVJAVHJI-UHFFFAOYSA-N 1-[(4-fluorophenyl)methyl]piperazine Chemical compound C1=CC(F)=CC=C1CN1CCNCC1 OOSZCNKVJAVHJI-UHFFFAOYSA-N 0.000 description 1
- DURPTKYDGMDSBL-UHFFFAOYSA-N 1-butoxybutane Chemical compound CCCCOCCCC DURPTKYDGMDSBL-UHFFFAOYSA-N 0.000 description 1
- 125000006218 1-ethylbutyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000006219 1-ethylpentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])[H] 0.000 description 1
- YMDZDFSUDFLGMX-UHFFFAOYSA-N 2-chloro-n-(2-chloroethyl)ethanamine;hydron;chloride Chemical compound [Cl-].ClCC[NH2+]CCCl YMDZDFSUDFLGMX-UHFFFAOYSA-N 0.000 description 1
- 125000006176 2-ethylbutyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(C([H])([H])*)C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000004493 2-methylbut-1-yl group Chemical group CC(C*)CC 0.000 description 1
- 125000005916 2-methylpentyl group Chemical group 0.000 description 1
- DFORIOBMTPKWPE-UHFFFAOYSA-N 3-(4-chlorobutanoyl)-1h-indole-5-carbonitrile Chemical compound C1=C(C#N)C=C2C(C(=O)CCCCl)=CNC2=C1 DFORIOBMTPKWPE-UHFFFAOYSA-N 0.000 description 1
- NJJWMEJWFYRORL-UHFFFAOYSA-N 3-(4-chlorobutyl)-1h-indole-5-carbonitrile Chemical compound C1=C(C#N)C=C2C(CCCCCl)=CNC2=C1 NJJWMEJWFYRORL-UHFFFAOYSA-N 0.000 description 1
- NVZMMERTOSZUEC-UHFFFAOYSA-N 3-[4-[4-(2-oxochromen-4-yl)piperazin-1-yl]butyl]-1h-indole-5-carboxylic acid Chemical compound C1=CC=CC2=C1OC(=O)C=C2N(CC1)CCN1CCCCC1=CNC2=CC=C(C(=O)O)C=C21 NVZMMERTOSZUEC-UHFFFAOYSA-N 0.000 description 1
- NPZKPZPSCLEGBJ-UHFFFAOYSA-N 3-[4-[4-(2-oxochromen-4-yl)piperazin-1-yl]butyl]-1h-indole-6-carboxylic acid Chemical compound C1=CC=CC2=C1OC(=O)C=C2N(CC1)CCN1CCCCC1=CNC2=CC(C(=O)O)=CC=C21 NPZKPZPSCLEGBJ-UHFFFAOYSA-N 0.000 description 1
- RBAKJQVMZUYLCK-UHFFFAOYSA-N 3-[4-[4-(2-oxochromen-6-yl)piperazin-1-yl]butyl]-1h-indole-5-carboxylic acid Chemical compound O1C(=O)C=CC2=CC(N3CCN(CC3)CCCCC3=CNC4=CC=C(C=C43)C(=O)O)=CC=C21 RBAKJQVMZUYLCK-UHFFFAOYSA-N 0.000 description 1
- UCYNYFXAFAFQKC-UHFFFAOYSA-N 3-[4-[4-(2-oxochromen-6-yl)piperazin-1-yl]butyl]-1h-indole-6-carbonitrile Chemical compound N#CC1=CC=C2C(CCCCN3CCN(CC3)C=3C=C4C=CC(OC4=CC=3)=O)=CNC2=C1 UCYNYFXAFAFQKC-UHFFFAOYSA-N 0.000 description 1
- XTLDFEGTVSDYEH-UHFFFAOYSA-N 3-[4-[4-(2-oxochromen-6-yl)piperazin-1-yl]butyl]-1h-indole-6-carboxylic acid Chemical compound O1C(=O)C=CC2=CC(N3CCN(CC3)CCCCC=3C4=CC=C(C=C4NC=3)C(=O)O)=CC=C21 XTLDFEGTVSDYEH-UHFFFAOYSA-N 0.000 description 1
- XNVYOFXFFBTIDU-UHFFFAOYSA-N 3-[4-[4-(7-chloro-2-oxochromen-4-yl)piperazin-1-yl]butyl]-1h-indole-5-carboxylic acid Chemical compound C1=C(Cl)C=CC2=C1OC(=O)C=C2N(CC1)CCN1CCCCC1=CNC2=CC=C(C(=O)O)C=C21 XNVYOFXFFBTIDU-UHFFFAOYSA-N 0.000 description 1
- WJGAYCUNIUIPDT-UHFFFAOYSA-N 3-[4-[4-(7-chloro-2-oxochromen-4-yl)piperazin-1-yl]butyl]-1h-indole-6-carboxylic acid Chemical compound C1=C(Cl)C=CC2=C1OC(=O)C=C2N(CC1)CCN1CCCCC1=CNC2=CC(C(=O)O)=CC=C21 WJGAYCUNIUIPDT-UHFFFAOYSA-N 0.000 description 1
- FHMYSQJDQDVVQA-UHFFFAOYSA-N 3-[4-[4-(7-chloro-2-oxochromen-6-yl)piperazin-1-yl]butyl]-1h-indole-5-carboxylic acid Chemical compound C1=CC(=O)OC(C=C2Cl)=C1C=C2N(CC1)CCN1CCCCC1=CNC2=CC=C(C(=O)O)C=C21 FHMYSQJDQDVVQA-UHFFFAOYSA-N 0.000 description 1
- MDZZDBYJBROHON-UHFFFAOYSA-N 3-[4-[4-(7-chloro-2-oxochromen-6-yl)piperazin-1-yl]butyl]-1h-indole-6-carboxylic acid Chemical compound C1=CC(=O)OC(C=C2Cl)=C1C=C2N(CC1)CCN1CCCCC1=CNC2=CC(C(=O)O)=CC=C21 MDZZDBYJBROHON-UHFFFAOYSA-N 0.000 description 1
- BCHMMDHJAQRJIZ-UHFFFAOYSA-N 3-[4-[4-(7-cyano-2-oxochromen-4-yl)piperazin-1-yl]butyl]-1h-indole-5-carboxylic acid Chemical compound C1=C(C#N)C=CC2=C1OC(=O)C=C2N(CC1)CCN1CCCCC1=CNC2=CC=C(C(=O)O)C=C21 BCHMMDHJAQRJIZ-UHFFFAOYSA-N 0.000 description 1
- FNGDEDFQRIKCRO-UHFFFAOYSA-N 3-[4-[4-(7-cyano-2-oxochromen-6-yl)piperazin-1-yl]butyl]-1h-indole-5-carboxylic acid Chemical compound C1=CC(=O)OC(C=C2C#N)=C1C=C2N(CC1)CCN1CCCCC1=CNC2=CC=C(C(=O)O)C=C21 FNGDEDFQRIKCRO-UHFFFAOYSA-N 0.000 description 1
- QIVKISMDICPYNX-UHFFFAOYSA-N 3-[4-[4-(7-cyano-2-oxochromen-6-yl)piperazin-1-yl]butyl]-1h-indole-6-carboxylic acid Chemical compound C1=CC(=O)OC(C=C2C#N)=C1C=C2N(CC1)CCN1CCCCC1=CNC2=CC(C(=O)O)=CC=C21 QIVKISMDICPYNX-UHFFFAOYSA-N 0.000 description 1
- FGMDPPMGPXZRIR-UHFFFAOYSA-N 3-[4-[4-(7-fluoro-2-oxochromen-4-yl)piperazin-1-yl]butyl]-1h-indole-5-carboxylic acid Chemical compound C1=C(F)C=CC2=C1OC(=O)C=C2N(CC1)CCN1CCCCC1=CNC2=CC=C(C(=O)O)C=C21 FGMDPPMGPXZRIR-UHFFFAOYSA-N 0.000 description 1
- LZLOGGJMASOUEG-UHFFFAOYSA-N 3-[4-[4-(7-fluoro-2-oxochromen-4-yl)piperazin-1-yl]butyl]-1h-indole-6-carboxylic acid Chemical compound C1=C(F)C=CC2=C1OC(=O)C=C2N(CC1)CCN1CCCCC1=CNC2=CC(C(=O)O)=CC=C21 LZLOGGJMASOUEG-UHFFFAOYSA-N 0.000 description 1
- VSYGSQIOIHZYTO-UHFFFAOYSA-N 3-[4-[4-(7-fluoro-2-oxochromen-6-yl)piperazin-1-yl]butyl]-1h-indole-5-carboxylic acid Chemical compound C1=CC(=O)OC(C=C2F)=C1C=C2N(CC1)CCN1CCCCC1=CNC2=CC=C(C(=O)O)C=C21 VSYGSQIOIHZYTO-UHFFFAOYSA-N 0.000 description 1
- XHKGJRISBSCABS-UHFFFAOYSA-N 3-[4-[4-(7-fluoro-2-oxochromen-6-yl)piperazin-1-yl]butyl]-1h-indole-6-carboxylic acid Chemical compound C1=CC(=O)OC(C=C2F)=C1C=C2N(CC1)CCN1CCCCC1=CNC2=CC(C(=O)O)=CC=C21 XHKGJRISBSCABS-UHFFFAOYSA-N 0.000 description 1
- RKZKNISMIBBAAJ-UHFFFAOYSA-N 3-[4-[4-(7-methoxy-2-oxochromen-4-yl)piperazin-1-yl]butyl]-1h-indole-5-carboxylic acid Chemical compound C1=C(C(O)=O)C=C2C(CCCCN3CCN(CC3)C=3C4=CC=C(C=C4OC(=O)C=3)OC)=CNC2=C1 RKZKNISMIBBAAJ-UHFFFAOYSA-N 0.000 description 1
- BUVNWKAPJYKAQV-UHFFFAOYSA-N 3-[4-[4-(7-methoxy-2-oxochromen-4-yl)piperazin-1-yl]butyl]-1h-indole-6-carboxylic acid Chemical compound OC(=O)C1=CC=C2C(CCCCN3CCN(CC3)C=3C4=CC=C(C=C4OC(=O)C=3)OC)=CNC2=C1 BUVNWKAPJYKAQV-UHFFFAOYSA-N 0.000 description 1
- YVVOMSMQPRPKMF-UHFFFAOYSA-N 3-[4-[4-(7-methoxy-2-oxochromen-6-yl)piperazin-1-yl]butyl]-1h-indole-6-carboxylic acid Chemical compound OC(=O)C1=CC=C2C(CCCCN3CCN(CC3)C3=CC=4C=CC(=O)OC=4C=C3OC)=CNC2=C1 YVVOMSMQPRPKMF-UHFFFAOYSA-N 0.000 description 1
- DBKSIASMFHVORU-UHFFFAOYSA-N 3-[4-[4-(7-methyl-2-oxochromen-4-yl)piperazin-1-yl]butyl]-1h-indole-5-carboxylic acid Chemical compound C1=C(C(O)=O)C=C2C(CCCCN3CCN(CC3)C=3C4=CC=C(C=C4OC(=O)C=3)C)=CNC2=C1 DBKSIASMFHVORU-UHFFFAOYSA-N 0.000 description 1
- MDJMJKLSJFTNCD-UHFFFAOYSA-N 3-[4-[4-(7-methyl-2-oxochromen-4-yl)piperazin-1-yl]butyl]-1h-indole-6-carboxylic acid Chemical compound OC(=O)C1=CC=C2C(CCCCN3CCN(CC3)C=3C4=CC=C(C=C4OC(=O)C=3)C)=CNC2=C1 MDJMJKLSJFTNCD-UHFFFAOYSA-N 0.000 description 1
- HCRRECXEYSJHPJ-UHFFFAOYSA-N 3-[4-[4-(7-methyl-2-oxochromen-6-yl)piperazin-1-yl]butyl]-1h-indole-5-carboxylic acid Chemical compound C1=C(C(O)=O)C=C2C(CCCCN3CCN(CC3)C3=CC=4C=CC(=O)OC=4C=C3C)=CNC2=C1 HCRRECXEYSJHPJ-UHFFFAOYSA-N 0.000 description 1
- ZAWWAUUVKKIDIK-UHFFFAOYSA-N 3-[4-[4-(7-methyl-2-oxochromen-6-yl)piperazin-1-yl]butyl]-1h-indole-6-carboxylic acid Chemical compound OC(=O)C1=CC=C2C(CCCCN3CCN(CC3)C3=CC=4C=CC(=O)OC=4C=C3C)=CNC2=C1 ZAWWAUUVKKIDIK-UHFFFAOYSA-N 0.000 description 1
- 125000005917 3-methylpentyl group Chemical group 0.000 description 1
- GTYYSTKKLLXTQW-UHFFFAOYSA-N 4-(5-fluoro-1h-indol-3-yl)butan-1-ol Chemical compound C1=C(F)C=C2C(CCCCO)=CNC2=C1 GTYYSTKKLLXTQW-UHFFFAOYSA-N 0.000 description 1
- IJAVCLNGRFTCBG-UHFFFAOYSA-N 4-(5-fluoro-1h-indol-3-yl)butanoic acid Chemical compound C1=C(F)C=C2C(CCCC(=O)O)=CNC2=C1 IJAVCLNGRFTCBG-UHFFFAOYSA-N 0.000 description 1
- YXJILBQVUGCMTK-UHFFFAOYSA-N 4-[4-[4-(1h-indol-3-yl)butyl]piperazin-1-yl]chromen-2-one Chemical compound C12=CC=CC=C2OC(=O)C=C1N1CCN(CCCCC=2C3=CC=CC=C3NC=2)CC1 YXJILBQVUGCMTK-UHFFFAOYSA-N 0.000 description 1
- HSGYPLYGZHITLI-UHFFFAOYSA-N 4-[4-[4-(5-chloro-1h-indol-3-yl)butyl]piperazin-1-yl]chromen-2-one Chemical compound C1=CC=CC2=C1OC(=O)C=C2N(CC1)CCN1CCCCC1=CNC2=CC=C(Cl)C=C21 HSGYPLYGZHITLI-UHFFFAOYSA-N 0.000 description 1
- CFIFETGVSOOGOH-UHFFFAOYSA-N 4-[4-[4-(5-methoxy-1h-indol-3-yl)butyl]piperazin-1-yl]chromen-2-one Chemical compound C1=CC=CC2=C1OC(=O)C=C2N(CC1)CCN1CCCCC1=CNC2=CC=C(OC)C=C21 CFIFETGVSOOGOH-UHFFFAOYSA-N 0.000 description 1
- CHUPULXBLDWVBO-UHFFFAOYSA-N 4-[4-[4-(6-chloro-1h-indol-3-yl)butyl]piperazin-1-yl]chromen-2-one Chemical compound C1=CC=CC2=C1OC(=O)C=C2N(CC1)CCN1CCCCC1=CNC2=CC(Cl)=CC=C21 CHUPULXBLDWVBO-UHFFFAOYSA-N 0.000 description 1
- ZXPBZLINQWBVKV-UHFFFAOYSA-N 4-[4-[4-(6-fluoro-1h-indol-3-yl)butyl]piperazin-1-yl]chromen-2-one Chemical compound C1=CC=CC2=C1OC(=O)C=C2N(CC1)CCN1CCCCC1=CNC2=CC(F)=CC=C21 ZXPBZLINQWBVKV-UHFFFAOYSA-N 0.000 description 1
- XXNMOZBGUPTRTP-UHFFFAOYSA-N 4-piperazin-1-ylchromen-2-one Chemical compound C12=CC=CC=C2OC(=O)C=C1N1CCNCC1 XXNMOZBGUPTRTP-UHFFFAOYSA-N 0.000 description 1
- LDCYZAJDBXYCGN-VIFPVBQESA-N 5-hydroxy-L-tryptophan Chemical compound C1=C(O)C=C2C(C[C@H](N)C(O)=O)=CNC2=C1 LDCYZAJDBXYCGN-VIFPVBQESA-N 0.000 description 1
- GKDAIJVDQYTUPC-UHFFFAOYSA-N 6-[4-[4-(1h-indol-3-yl)butyl]piperazin-1-yl]chromen-2-one Chemical compound C1=CC=C2C(CCCCN3CCN(CC3)C=3C=C4C=CC(OC4=CC=3)=O)=CNC2=C1 GKDAIJVDQYTUPC-UHFFFAOYSA-N 0.000 description 1
- MSEKXTTUXYOTGF-UHFFFAOYSA-N 6-[4-[4-(5-chloro-1h-indol-3-yl)butyl]piperazin-1-yl]-7-hydroxychromen-2-one Chemical compound C1=C(Cl)C=C2C(CCCCN3CCN(CC3)C3=CC=4C=CC(=O)OC=4C=C3O)=CNC2=C1 MSEKXTTUXYOTGF-UHFFFAOYSA-N 0.000 description 1
- VBZHIMGPSHPSTB-UHFFFAOYSA-N 6-[4-[4-(5-chloro-1h-indol-3-yl)butyl]piperazin-1-yl]chromen-2-one Chemical compound O1C(=O)C=CC2=CC(N3CCN(CC3)CCCCC3=CNC4=CC=C(C=C43)Cl)=CC=C21 VBZHIMGPSHPSTB-UHFFFAOYSA-N 0.000 description 1
- SUGRZGOEUJRSSH-UHFFFAOYSA-N 6-[4-[4-(5-fluoro-1h-indol-3-yl)butyl]piperazin-1-yl]-7-hydroxychromen-2-one Chemical compound C1=C(F)C=C2C(CCCCN3CCN(CC3)C3=CC=4C=CC(=O)OC=4C=C3O)=CNC2=C1 SUGRZGOEUJRSSH-UHFFFAOYSA-N 0.000 description 1
- HJLOFLRJTOVWNH-UHFFFAOYSA-N 6-[4-[4-(5-methoxy-1h-indol-3-yl)butyl]piperazin-1-yl]chromen-2-one Chemical compound O1C(=O)C=CC2=CC(N3CCN(CC3)CCCCC3=CNC4=CC=C(C=C43)OC)=CC=C21 HJLOFLRJTOVWNH-UHFFFAOYSA-N 0.000 description 1
- XEFVDKBYOQFSGM-UHFFFAOYSA-N 6-[4-[4-(6-chloro-1h-indol-3-yl)butyl]piperazin-1-yl]-7-hydroxychromen-2-one Chemical compound ClC1=CC=C2C(CCCCN3CCN(CC3)C3=CC=4C=CC(=O)OC=4C=C3O)=CNC2=C1 XEFVDKBYOQFSGM-UHFFFAOYSA-N 0.000 description 1
- BLLSDVVSWZOANP-UHFFFAOYSA-N 6-[4-[4-(6-chloro-1h-indol-3-yl)butyl]piperazin-1-yl]chromen-2-one Chemical compound O1C(=O)C=CC2=CC(N3CCN(CC3)CCCCC=3C4=CC=C(C=C4NC=3)Cl)=CC=C21 BLLSDVVSWZOANP-UHFFFAOYSA-N 0.000 description 1
- DCHCGYANXVXNMM-UHFFFAOYSA-N 6-[4-[4-(6-fluoro-1h-indol-3-yl)butyl]piperazin-1-yl]chromen-2-one Chemical compound O1C(=O)C=CC2=CC(N3CCN(CC3)CCCCC=3C4=CC=C(C=C4NC=3)F)=CC=C21 DCHCGYANXVXNMM-UHFFFAOYSA-N 0.000 description 1
- FEVRGRBUPLNGGV-UHFFFAOYSA-N 6-[4-[4-(6-methoxy-1h-indol-3-yl)butyl]piperazin-1-yl]chromen-2-one Chemical compound O1C(=O)C=CC2=CC(N3CCN(CC3)CCCCC=3C4=CC=C(C=C4NC=3)OC)=CC=C21 FEVRGRBUPLNGGV-UHFFFAOYSA-N 0.000 description 1
- PNAPEVZJBOBING-UHFFFAOYSA-N 6-piperazin-1-ylchromen-2-one Chemical compound C=1C=C2OC(=O)C=CC2=CC=1N1CCNCC1 PNAPEVZJBOBING-UHFFFAOYSA-N 0.000 description 1
- YZQIPNIXUJPFEN-UHFFFAOYSA-N 6-piperazin-1-ylchromen-2-one hydrochloride Chemical compound Cl.O=c1ccc2cc(ccc2o1)N1CCNCC1 YZQIPNIXUJPFEN-UHFFFAOYSA-N 0.000 description 1
- QAYPRMWWZPFMDO-UHFFFAOYSA-N 7-hydroxy-6-[4-[4-(1h-indol-3-yl)butyl]piperazin-1-yl]chromen-2-one Chemical compound C1=CC=C2C(CCCCN3CCN(CC3)C3=CC=4C=CC(=O)OC=4C=C3O)=CNC2=C1 QAYPRMWWZPFMDO-UHFFFAOYSA-N 0.000 description 1
- 206010000599 Acromegaly Diseases 0.000 description 1
- 229910000761 Aluminium amalgam Inorganic materials 0.000 description 1
- 201000000736 Amenorrhea Diseases 0.000 description 1
- 206010001928 Amenorrhoea Diseases 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- 229910015900 BF3 Inorganic materials 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical class OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 1
- 125000005947 C1-C6 alkylsulfonyloxy group Chemical group 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- 241000700199 Cavia porcellus Species 0.000 description 1
- 208000018152 Cerebral disease Diseases 0.000 description 1
- KZBUYRJDOAKODT-UHFFFAOYSA-N Chlorine Chemical compound ClCl KZBUYRJDOAKODT-UHFFFAOYSA-N 0.000 description 1
- QOSSAOTZNIDXMA-UHFFFAOYSA-N Dicylcohexylcarbodiimide Chemical compound C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 description 1
- GKQLYSROISKDLL-UHFFFAOYSA-N EEDQ Chemical compound C1=CC=C2N(C(=O)OCC)C(OCC)C=CC2=C1 GKQLYSROISKDLL-UHFFFAOYSA-N 0.000 description 1
- 238000006783 Fischer indole synthesis reaction Methods 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 206010058359 Hypogonadism Diseases 0.000 description 1
- HCUARRIEZVDMPT-UHFFFAOYSA-N Indole-2-carboxylic acid Chemical compound C1=CC=C2NC(C(=O)O)=CC2=C1 HCUARRIEZVDMPT-UHFFFAOYSA-N 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- WTDRDQBEARUVNC-UHFFFAOYSA-N L-Dopa Natural products OC(=O)C(N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-UHFFFAOYSA-N 0.000 description 1
- 208000026139 Memory disease Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- FXHOOIRPVKKKFG-UHFFFAOYSA-N N,N-Dimethylacetamide Chemical compound CN(C)C(C)=O FXHOOIRPVKKKFG-UHFFFAOYSA-N 0.000 description 1
- JLTDJTHDQAWBAV-UHFFFAOYSA-N N,N-dimethylaniline Chemical compound CN(C)C1=CC=CC=C1 JLTDJTHDQAWBAV-UHFFFAOYSA-N 0.000 description 1
- NQTADLQHYWFPDB-UHFFFAOYSA-N N-Hydroxysuccinimide Chemical compound ON1C(=O)CCC1=O NQTADLQHYWFPDB-UHFFFAOYSA-N 0.000 description 1
- AMQJEAYHLZJPGS-UHFFFAOYSA-N N-Pentanol Chemical compound CCCCCO AMQJEAYHLZJPGS-UHFFFAOYSA-N 0.000 description 1
- PHSPJQZRQAJPPF-UHFFFAOYSA-N N-alpha-Methylhistamine Chemical compound CNCCC1=CN=CN1 PHSPJQZRQAJPPF-UHFFFAOYSA-N 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 1
- DYHZQWRVKBFGTM-UHFFFAOYSA-N O=C1OC2=C(C(=C1)N1CCN(CC1)CCCCC=1NC3=CC=C(C=C3C=1)C#N)C=CC=C2 Chemical compound O=C1OC2=C(C(=C1)N1CCN(CC1)CCCCC=1NC3=CC=C(C=C3C=1)C#N)C=CC=C2 DYHZQWRVKBFGTM-UHFFFAOYSA-N 0.000 description 1
- 208000027089 Parkinsonian disease Diseases 0.000 description 1
- 206010034010 Parkinsonism Diseases 0.000 description 1
- 239000004264 Petrolatum Substances 0.000 description 1
- 208000007222 Physiological Sexual Dysfunction Diseases 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 206010036618 Premenstrual syndrome Diseases 0.000 description 1
- 239000007868 Raney catalyst Substances 0.000 description 1
- 229910000564 Raney nickel Inorganic materials 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- 230000009102 absorption Effects 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 230000001476 alcoholic effect Effects 0.000 description 1
- 125000002723 alicyclic group Chemical group 0.000 description 1
- 125000001931 aliphatic group Chemical group 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 229910001854 alkali hydroxide Inorganic materials 0.000 description 1
- 229910000272 alkali metal oxide Inorganic materials 0.000 description 1
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 1
- CJCSPKMFHVPWAR-JTQLQIEISA-N alpha-methyl-L-dopa Chemical compound OC(=O)[C@](N)(C)CC1=CC=C(O)C(O)=C1 CJCSPKMFHVPWAR-JTQLQIEISA-N 0.000 description 1
- 231100000540 amenorrhea Toxicity 0.000 description 1
- 239000003708 ampul Substances 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 150000008064 anhydrides Chemical class 0.000 description 1
- 230000008485 antagonism Effects 0.000 description 1
- 229940030600 antihypertensive agent Drugs 0.000 description 1
- 239000002220 antihypertensive agent Substances 0.000 description 1
- 229940054051 antipsychotic indole derivative Drugs 0.000 description 1
- 239000003420 antiserotonin agent Substances 0.000 description 1
- 230000036506 anxiety Effects 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 229960000686 benzalkonium chloride Drugs 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-N benzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 description 1
- 229940092714 benzenesulfonic acid Drugs 0.000 description 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid group Chemical group C(C1=CC=CC=C1)(=O)O WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
- 235000019445 benzyl alcohol Nutrition 0.000 description 1
- 150000003938 benzyl alcohols Chemical class 0.000 description 1
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 description 1
- 125000000051 benzyloxy group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])O* 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- AZWXAPCAJCYGIA-UHFFFAOYSA-N bis(2-methylpropyl)alumane Chemical compound CC(C)C[AlH]CC(C)C AZWXAPCAJCYGIA-UHFFFAOYSA-N 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- OZVBMTJYIDMWIL-AYFBDAFISA-N bromocriptine Chemical compound C1=CC(C=2[C@H](N(C)C[C@@H](C=2)C(=O)N[C@]2(C(=O)N3[C@H](C(N4CCC[C@H]4[C@]3(O)O2)=O)CC(C)C)C(C)C)C2)=C3C2=C(Br)NC3=C1 OZVBMTJYIDMWIL-AYFBDAFISA-N 0.000 description 1
- 229960002802 bromocriptine Drugs 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 150000001718 carbodiimides Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 150000004649 carbonic acid derivatives Chemical class 0.000 description 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 238000009903 catalytic hydrogenation reaction Methods 0.000 description 1
- 229940110456 cocoa butter Drugs 0.000 description 1
- 235000019868 cocoa butter Nutrition 0.000 description 1
- 230000007278 cognition impairment Effects 0.000 description 1
- 230000008602 contraction Effects 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 125000004093 cyano group Chemical group *C#N 0.000 description 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 239000012024 dehydrating agents Substances 0.000 description 1
- 238000001212 derivatisation Methods 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 125000001028 difluoromethyl group Chemical group [H]C(F)(F)* 0.000 description 1
- SBZXBUIDTXKZTM-UHFFFAOYSA-N diglyme Chemical compound COCCOCCOC SBZXBUIDTXKZTM-UHFFFAOYSA-N 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-M dihydrogenphosphate Chemical compound OP(O)([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-M 0.000 description 1
- SIPUZPBQZHNSDW-UHFFFAOYSA-N diisobutylaluminium hydride Substances CC(C)C[Al]CC(C)C SIPUZPBQZHNSDW-UHFFFAOYSA-N 0.000 description 1
- 125000002147 dimethylamino group Chemical group [H]C([H])([H])N(*)C([H])([H])[H] 0.000 description 1
- MHUWZNTUIIFHAS-CLFAGFIQSA-N dioleoyl phosphatidic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC(COP(O)(O)=O)OC(=O)CCCCCCC\C=C/CCCCCCCC MHUWZNTUIIFHAS-CLFAGFIQSA-N 0.000 description 1
- MKRTXPORKIRPDG-UHFFFAOYSA-N diphenylphosphoryl azide Chemical compound C=1C=CC=CC=1P(=O)(N=[N+]=[N-])C1=CC=CC=C1 MKRTXPORKIRPDG-UHFFFAOYSA-N 0.000 description 1
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- MOTZDAYCYVMXPC-UHFFFAOYSA-N dodecyl hydrogen sulfate Chemical compound CCCCCCCCCCCCOS(O)(=O)=O MOTZDAYCYVMXPC-UHFFFAOYSA-N 0.000 description 1
- 239000006196 drop Substances 0.000 description 1
- 239000000890 drug combination Substances 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- AFAXGSQYZLGZPG-UHFFFAOYSA-N ethanedisulfonic acid Chemical compound OS(=O)(=O)CCS(O)(=O)=O AFAXGSQYZLGZPG-UHFFFAOYSA-N 0.000 description 1
- CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 239000003889 eye drop Substances 0.000 description 1
- 229940012356 eye drops Drugs 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 125000004216 fluoromethyl group Chemical group [H]C([H])(F)* 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 239000012458 free base Substances 0.000 description 1
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 150000008282 halocarbons Chemical class 0.000 description 1
- 229910052736 halogen Inorganic materials 0.000 description 1
- 150000002366 halogen compounds Chemical class 0.000 description 1
- 125000005843 halogen group Chemical group 0.000 description 1
- 150000002367 halogens Chemical group 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 125000000623 heterocyclic group Chemical group 0.000 description 1
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 229910000042 hydrogen bromide Inorganic materials 0.000 description 1
- MSQACBWWAIBWIC-UHFFFAOYSA-N hydron;piperazine;chloride Chemical compound Cl.C1CNCCN1 MSQACBWWAIBWIC-UHFFFAOYSA-N 0.000 description 1
- 239000005457 ice water Substances 0.000 description 1
- 210000003405 ileum Anatomy 0.000 description 1
- 239000007943 implant Substances 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- PZOUSPYUWWUPPK-UHFFFAOYSA-N indole Natural products CC1=CC=CC2=C1C=CN2 PZOUSPYUWWUPPK-UHFFFAOYSA-N 0.000 description 1
- RKJUIXBNRJVNHR-UHFFFAOYSA-N indolenine Natural products C1=CC=C2CC=NC2=C1 RKJUIXBNRJVNHR-UHFFFAOYSA-N 0.000 description 1
- 150000002475 indoles Chemical class 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 150000002497 iodine compounds Chemical class 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 125000004491 isohexyl group Chemical group C(CCC(C)C)* 0.000 description 1
- 125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 230000006651 lactation Effects 0.000 description 1
- 201000010901 lateral sclerosis Diseases 0.000 description 1
- 229960004502 levodopa Drugs 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- AMXOYNBUYSYVKV-UHFFFAOYSA-M lithium bromide Chemical compound [Li+].[Br-] AMXOYNBUYSYVKV-UHFFFAOYSA-M 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 150000002739 metals Chemical class 0.000 description 1
- QARBMVPHQWIHKH-UHFFFAOYSA-N methanesulfonyl chloride Chemical compound CS(Cl)(=O)=O QARBMVPHQWIHKH-UHFFFAOYSA-N 0.000 description 1
- 125000005948 methanesulfonyloxy group Chemical group 0.000 description 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 1
- 125000001160 methoxycarbonyl group Chemical group [H]C([H])([H])OC(*)=O 0.000 description 1
- BWIGVPKCMIIOLS-UHFFFAOYSA-N methyl 3-[4-[4-(2-oxochromen-4-yl)piperazin-1-yl]butyl]-1h-indole-6-carboxylate Chemical compound C1=CC=CC2=C1OC(=O)C=C2N(CC1)CCN1CCCCC1=CNC2=CC(C(=O)OC)=CC=C21 BWIGVPKCMIIOLS-UHFFFAOYSA-N 0.000 description 1
- YZESDZVNDIDRSV-UHFFFAOYSA-N methyl 3-[4-[4-(2-oxochromen-6-yl)piperazin-1-yl]butyl]-1h-indole-5-carboxylate Chemical compound O1C(=O)C=CC2=CC(N3CCN(CC3)CCCCC3=CNC4=CC=C(C=C43)C(=O)OC)=CC=C21 YZESDZVNDIDRSV-UHFFFAOYSA-N 0.000 description 1
- GGEDHKJXLYMIAF-UHFFFAOYSA-N methyl 3-[4-[4-(7-fluoro-2-oxochromen-4-yl)piperazin-1-yl]butyl]-1h-indole-6-carboxylate Chemical compound C1=C(F)C=CC2=C1OC(=O)C=C2N(CC1)CCN1CCCCC1=CNC2=CC(C(=O)OC)=CC=C21 GGEDHKJXLYMIAF-UHFFFAOYSA-N 0.000 description 1
- BQLNCEJPRCHPBN-UHFFFAOYSA-N methyl 3-[4-[4-(7-methyl-2-oxochromen-6-yl)piperazin-1-yl]butyl]-1h-indole-5-carboxylate Chemical compound C1=CC(=O)OC(C=C2C)=C1C=C2N(CC1)CCN1CCCCC1=CNC2=CC=C(C(=O)OC)C=C21 BQLNCEJPRCHPBN-UHFFFAOYSA-N 0.000 description 1
- 125000000250 methylamino group Chemical group [H]N(*)C([H])([H])[H] 0.000 description 1
- 206010027599 migraine Diseases 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 208000005264 motor neuron disease Diseases 0.000 description 1
- LNOPIUAQISRISI-UHFFFAOYSA-N n'-hydroxy-2-propan-2-ylsulfonylethanimidamide Chemical compound CC(C)S(=O)(=O)CC(N)=NO LNOPIUAQISRISI-UHFFFAOYSA-N 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000002004 n-butylamino group Chemical group [H]N(*)C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- YZMHQCWXYHARLS-UHFFFAOYSA-N naphthalene-1,2-disulfonic acid Chemical compound C1=CC=CC2=C(S(O)(=O)=O)C(S(=O)(=O)O)=CC=C21 YZMHQCWXYHARLS-UHFFFAOYSA-N 0.000 description 1
- PSZYNBSKGUBXEH-UHFFFAOYSA-N naphthalene-1-sulfonic acid Chemical compound C1=CC=C2C(S(=O)(=O)O)=CC=CC2=C1 PSZYNBSKGUBXEH-UHFFFAOYSA-N 0.000 description 1
- 125000001971 neopentyl group Chemical group [H]C([*])([H])C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 210000001577 neostriatum Anatomy 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 1
- 238000007339 nucleophilic aromatic substitution reaction Methods 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 239000012074 organic phase Substances 0.000 description 1
- 238000006053 organic reaction Methods 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 125000004430 oxygen atom Chemical group O* 0.000 description 1
- WWPITPSIWMXDPE-UHFFFAOYSA-N para-chloroamphetamine Chemical compound CC(N)CC1=CC=C(Cl)C=C1 WWPITPSIWMXDPE-UHFFFAOYSA-N 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 125000006340 pentafluoro ethyl group Chemical group FC(F)(F)C(F)(F)* 0.000 description 1
- 125000003538 pentan-3-yl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 1
- 238000010647 peptide synthesis reaction Methods 0.000 description 1
- 229940066842 petrolatum Drugs 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 150000003016 phosphoric acids Chemical class 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- FYRHIOVKTDQVFC-UHFFFAOYSA-M potassium phthalimide Chemical compound [K+].C1=CC=C2C(=O)[N-]C(=O)C2=C1 FYRHIOVKTDQVFC-UHFFFAOYSA-M 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 150000003138 primary alcohols Chemical class 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- 230000035484 reaction time Effects 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 125000003548 sec-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 230000000862 serotonergic effect Effects 0.000 description 1
- 239000003723 serotonin 1A agonist Substances 0.000 description 1
- 239000000952 serotonin receptor agonist Substances 0.000 description 1
- 208000012201 sexual and gender identity disease Diseases 0.000 description 1
- 208000015891 sexual disease Diseases 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 238000010898 silica gel chromatography Methods 0.000 description 1
- 229910001023 sodium amalgam Inorganic materials 0.000 description 1
- 229940074545 sodium dihydrogen phosphate dihydrate Drugs 0.000 description 1
- 229910052938 sodium sulfate Inorganic materials 0.000 description 1
- 235000011152 sodium sulphate Nutrition 0.000 description 1
- 239000008347 soybean phospholipid Substances 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 125000000542 sulfonic acid group Chemical group 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical compound C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 description 1
- 125000004213 tert-butoxy group Chemical group [H]C([H])([H])C(O*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 125000006318 tert-butyl amino group Chemical group [H]N(*)C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 150000003512 tertiary amines Chemical class 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000004809 thin layer chromatography Methods 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 239000000196 tragacanth Substances 0.000 description 1
- 235000010487 tragacanth Nutrition 0.000 description 1
- 229940116362 tragacanth Drugs 0.000 description 1
- ILJSQTXMGCGYMG-UHFFFAOYSA-N triacetic acid Chemical compound CC(=O)CC(=O)CC(O)=O ILJSQTXMGCGYMG-UHFFFAOYSA-N 0.000 description 1
- PVFOMCVHYWHZJE-UHFFFAOYSA-N trichloroacetyl chloride Chemical compound ClC(=O)C(Cl)(Cl)Cl PVFOMCVHYWHZJE-UHFFFAOYSA-N 0.000 description 1
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 239000008096 xylene Substances 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Psychiatry (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Hospice & Palliative Care (AREA)
- Pain & Pain Management (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE19730989A DE19730989A1 (de) | 1997-07-18 | 1997-07-18 | Piperazin-Derivate |
| PCT/EP1998/003956 WO1999003855A1 (de) | 1997-07-18 | 1998-06-29 | Piperazin-derivate |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SK352000A3 true SK352000A3 (en) | 2000-06-12 |
Family
ID=7836208
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SK35-2000A SK352000A3 (en) | 1997-07-18 | 1998-06-29 | Piperazine derivatives, process for its preparation and pharmaceutical composition containing same |
Country Status (23)
| Country | Link |
|---|---|
| US (1) | US6251908B1 (ru) |
| EP (1) | EP0998474B1 (ru) |
| JP (1) | JP2001510193A (ru) |
| KR (1) | KR100528684B1 (ru) |
| CN (1) | CN1093127C (ru) |
| AR (1) | AR010932A1 (ru) |
| AT (1) | ATE353326T1 (ru) |
| AU (1) | AU731332B2 (ru) |
| BR (1) | BR9810607A (ru) |
| CA (1) | CA2296687A1 (ru) |
| DE (2) | DE19730989A1 (ru) |
| ES (1) | ES2281131T3 (ru) |
| HU (1) | HUP0002718A3 (ru) |
| ID (1) | ID24663A (ru) |
| MY (1) | MY132794A (ru) |
| NO (1) | NO20000216L (ru) |
| PL (1) | PL191078B1 (ru) |
| RU (1) | RU2194048C2 (ru) |
| SK (1) | SK352000A3 (ru) |
| TW (1) | TW425398B (ru) |
| UA (1) | UA59407C2 (ru) |
| WO (1) | WO1999003855A1 (ru) |
| ZA (1) | ZA986390B (ru) |
Families Citing this family (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HUP0203194A3 (en) * | 1999-08-23 | 2004-01-28 | Solvay Pharm Bv | Phenylpiperazines, pharmaceutical compositions containing them and their use |
| JP2004513924A (ja) * | 2000-11-14 | 2004-05-13 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフトング | 組み合わせた５−ｈｔ１ａアゴニストおよびセロトニン再取り込み阻害剤の新規な使用 |
| AR032712A1 (es) * | 2001-02-21 | 2003-11-19 | Solvay Pharm Bv | Un mesilato de derivados de fenilpiperazina y composiciones farmaceuticas que lo contienen |
| DE10112151A1 (de) * | 2001-03-14 | 2002-09-19 | Merck Patent Gmbh | Substituierte Benzofuran-2-carbonsäureamide |
| EP1408976B3 (en) | 2001-07-20 | 2010-08-25 | Psychogenics Inc. | Treatment for attention-deficit hyperactivity disorder |
| US20030045449A1 (en) * | 2001-08-15 | 2003-03-06 | Pfizer, Inc. | Pharmaceutical combinations for the treatment of neurodegenerative diseases |
| DE10217006A1 (de) * | 2002-04-16 | 2003-11-06 | Merck Patent Gmbh | Substituierte Indole |
| DE10259244A1 (de) * | 2002-12-17 | 2004-07-01 | Merck Patent Gmbh | N-(Indolethyl-)cycloamin-Verbindungen |
| DE10305739A1 (de) * | 2003-02-11 | 2004-08-19 | Merck Patent Gmbh | Benzofuranderivate |
| DE10315285A1 (de) | 2003-04-04 | 2004-10-14 | Merck Patent Gmbh | Chromenonindole |
| GT200600414A (es) * | 2005-09-12 | 2007-09-20 | Sal de glucuranato de compuesto de piperazine | |
| US9066903B2 (en) | 2006-02-28 | 2015-06-30 | The United States Of America As Represented By The Department Of Veterans Affairs | Pharmacological treatment of Parkinson's disease |
| RU2329044C1 (ru) * | 2006-11-16 | 2008-07-20 | Андрей Александрович Иващенко | Лиганды 5-ht6 рецепторов, фармацевтическая композиция, способ ее получения и лекарственное средство |
| US8334402B2 (en) * | 2008-04-17 | 2012-12-18 | Thomas Daly | Biological buffers with wide buffering ranges |
| US8822728B2 (en) | 2008-04-17 | 2014-09-02 | Thomas Daly | Biological buffers with wide buffering ranges |
| US8034951B2 (en) * | 2008-04-17 | 2011-10-11 | Thomas Daly | Biological buffers with wide buffering ranges |
| US8519141B2 (en) | 2008-04-17 | 2013-08-27 | Thomas Daly | Biological buffers with wide buffering ranges |
| US7939659B2 (en) * | 2008-04-17 | 2011-05-10 | Thomas Daly | Biological buffers with wide buffering ranges |
| US7635791B2 (en) * | 2008-04-17 | 2009-12-22 | Tpat Ip Llc | Biological buffers with wide buffering ranges |
| US20170313920A1 (en) | 2010-10-06 | 2017-11-02 | Thomas P. Daly | Biological Buffers with Wide Buffering Ranges |
| US9090638B2 (en) | 2008-04-17 | 2015-07-28 | Thomas Daly | Biological buffers with wide buffering ranges |
| US9447310B2 (en) | 2008-04-17 | 2016-09-20 | Thomas P. Daly | Biological buffers with wide buffering ranges |
| AU2009255333B2 (en) * | 2008-05-30 | 2015-07-09 | Psychogenics, Inc. | Treatment for neurological and mental disorders |
| NZ596595A (en) | 2009-05-12 | 2013-05-31 | Transgene Sa | Method for orthopoxvirus production and purification |
| CN102206214B (zh) * | 2011-04-07 | 2014-03-12 | 华中科技大学 | 苯并吡喃酮类衍生物及其应用 |
| US9475754B2 (en) | 2011-10-06 | 2016-10-25 | Thomas P. Daly | Biological buffers with wide buffering ranges |
| WO2013174876A1 (en) * | 2012-05-23 | 2013-11-28 | Nerviano Medical Sciences S.R.L. | Process for the preparation of n-[5-(3,5-difluoro-benzyl)-1h-indazol-3-yl]-4-(4-methyl-piperazin-1-yl)-2-(tetrahydro-pyran-4-ylamino)-benzamide |
| WO2015014256A1 (en) | 2013-07-29 | 2015-02-05 | Sunshine Lake Pharma Co., Ltd. | Substituted heteroaryl compounds and methods of use thereof |
| CN105418506B (zh) * | 2014-09-19 | 2018-04-24 | 上海医药工业研究院 | 乙酰苄胺哌嗪类衍生物及其作为脑神经保护剂的应用 |
| US10316025B2 (en) | 2015-06-03 | 2019-06-11 | Sunshine Lake Pharma Co., Ltd. | Substituted piperazine compounds and methods of use and use thereof |
| CN120817935A (zh) * | 2024-04-15 | 2025-10-21 | 复旦大学附属肿瘤医院 | 一种杂(芳)环取代环状二胺类化合物及其在制备治疗和/或预防肿瘤药物中的应用 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB146691A (en) * | 1919-05-29 | 1920-07-15 | William Herbert Tripp | Apparatus for indicating and recording side drift or leeway of aircraft |
| FR2189027B1 (ru) * | 1972-06-21 | 1976-03-05 | Leurquin Laboratoires Fr | |
| DE4333254A1 (de) * | 1993-09-30 | 1995-04-06 | Merck Patent Gmbh | Piperidine und Piperazine |
| GB9514901D0 (en) * | 1995-07-20 | 1995-09-20 | American Home Prod | Piperazine derivatives |
| HUP9902456A3 (en) * | 1996-07-26 | 2002-04-29 | Nissan Chemical Ind Ltd | Chroman derivatives |
| ATE252575T1 (de) * | 1997-07-25 | 2003-11-15 | Lundbeck & Co As H | Indole und 2,3-dihydroindolderivate, ihre herstellung und verwendung |
-
1997
- 1997-07-18 DE DE19730989A patent/DE19730989A1/de not_active Withdrawn
-
1998
- 1998-06-29 CN CN98807377A patent/CN1093127C/zh not_active Expired - Fee Related
- 1998-06-29 US US09/462,468 patent/US6251908B1/en not_active Expired - Fee Related
- 1998-06-29 ID IDW20000151A patent/ID24663A/id unknown
- 1998-06-29 ES ES98938671T patent/ES2281131T3/es not_active Expired - Lifetime
- 1998-06-29 AT AT98938671T patent/ATE353326T1/de not_active IP Right Cessation
- 1998-06-29 SK SK35-2000A patent/SK352000A3/sk unknown
- 1998-06-29 RU RU2000102920/04A patent/RU2194048C2/ru not_active IP Right Cessation
- 1998-06-29 AU AU87302/98A patent/AU731332B2/en not_active Ceased
- 1998-06-29 PL PL338075A patent/PL191078B1/pl not_active IP Right Cessation
- 1998-06-29 WO PCT/EP1998/003956 patent/WO1999003855A1/de not_active Ceased
- 1998-06-29 EP EP98938671A patent/EP0998474B1/de not_active Expired - Lifetime
- 1998-06-29 KR KR10-2000-7000522A patent/KR100528684B1/ko not_active Expired - Fee Related
- 1998-06-29 UA UA2000020920A patent/UA59407C2/ru unknown
- 1998-06-29 JP JP2000503079A patent/JP2001510193A/ja active Pending
- 1998-06-29 CA CA002296687A patent/CA2296687A1/en not_active Abandoned
- 1998-06-29 DE DE59813899T patent/DE59813899D1/de not_active Expired - Fee Related
- 1998-06-29 HU HU0002718A patent/HUP0002718A3/hu unknown
- 1998-06-29 BR BR9810607-4A patent/BR9810607A/pt not_active Application Discontinuation
- 1998-07-16 MY MYPI98003262A patent/MY132794A/en unknown
- 1998-07-17 TW TW087111694A patent/TW425398B/zh not_active IP Right Cessation
- 1998-07-17 AR ARP980103491A patent/AR010932A1/es unknown
- 1998-07-17 ZA ZA986390A patent/ZA986390B/xx unknown
-
2000
- 2000-01-17 NO NO20000216A patent/NO20000216L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| EP0998474A1 (de) | 2000-05-10 |
| NO20000216D0 (no) | 2000-01-17 |
| CN1264379A (zh) | 2000-08-23 |
| ATE353326T1 (de) | 2007-02-15 |
| KR20010021957A (ko) | 2001-03-15 |
| AU731332B2 (en) | 2001-03-29 |
| MY132794A (en) | 2007-10-31 |
| HUP0002718A2 (hu) | 2001-10-28 |
| JP2001510193A (ja) | 2001-07-31 |
| NO20000216L (no) | 2000-01-17 |
| ZA986390B (en) | 1999-05-24 |
| PL338075A1 (en) | 2000-09-25 |
| KR100528684B1 (ko) | 2005-11-15 |
| HUP0002718A3 (en) | 2001-11-28 |
| CA2296687A1 (en) | 1999-01-28 |
| TW425398B (en) | 2001-03-11 |
| AR010932A1 (es) | 2000-07-12 |
| EP0998474B1 (de) | 2007-02-07 |
| WO1999003855A1 (de) | 1999-01-28 |
| CN1093127C (zh) | 2002-10-23 |
| PL191078B1 (pl) | 2006-03-31 |
| BR9810607A (pt) | 2000-07-11 |
| AU8730298A (en) | 1999-02-10 |
| DE59813899D1 (de) | 2007-03-22 |
| UA59407C2 (ru) | 2003-09-15 |
| DE19730989A1 (de) | 1999-01-21 |
| ES2281131T3 (es) | 2007-09-16 |
| US6251908B1 (en) | 2001-06-26 |
| RU2194048C2 (ru) | 2002-12-10 |
| ID24663A (id) | 2000-07-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SK352000A3 (en) | Piperazine derivatives, process for its preparation and pharmaceutical composition containing same | |
| RU2132848C1 (ru) | Производные пиперидина и пиперазина, способ их получения, содержащие их фармацевтические композиции и способ их получения | |
| US5242925A (en) | Piperazinylbenzodioxane derivatives | |
| JP3327473B2 (ja) | インドール誘導体 | |
| CA2147451C (en) | 3-indolylpiperidines | |
| SK281080B6 (sk) | Derivát indolpiperidínu, spôsob jeho prípravy a farmaceutický prostriedok, ktorý ho obsahuje a jeho použitie | |
| SK30399A3 (en) | D4 receptor selectivity piperazine derivatives | |
| US6509340B1 (en) | Amide and urea derivatives as 5-HT reuptake inhibitors and as 5-HT1B/1D ligands | |
| US6333339B1 (en) | 3-Benzylpiperidine | |
| RU2211216C2 (ru) | Производные амидов и мочевины в качестве ингибиторов вторичного поглощения 5-ht и лигандов 5-ht1b/1d | |
| CZ200077A3 (cs) | Derivát piperazinu, způsob jeho přípravy a farmaceutický prostředek, který ho obsahuje | |
| US20030064995A1 (en) | Amide and urea derivatives as 5-HT reuptake inhibitors and as5-HT1B/1D ligands | |
| CZ450999A3 (cs) | Derivát 3-benzylpiperidinu, způsob jeho přípravy a farmaceutický prostředek, který ho obsahuje | |
| MXPA00000615A (en) | Piperazine derivatives | |
| MXPA01006500A (es) | Derivados de amida y urea como inhibidores de reabsorcion de 5-ht y como ligandos 5-ht1b/1d | |
| KR20010112231A (ko) | ５―ｈｔ 재흡수 저해제 및 ５―ｈｔ１ｂ／１ｄ리간드로서의 아미드 및 우레아 유도체 |